Literature DB >> 23751044

Two cases of prenatally diagnosed sacrococcygeal teratoma type I with different clinical features.

Shinobu Goto1, Nobuhiro Suzumori, Shintaro Obayashi, Yasuhiko Ozaki, Mayumi Sugiura-Ogasawara.   

Abstract

Sacrococcygeal teratoma (SCT) is a rare congenital disease and prognostic factors have not been entirely established. We report two cases of fetal SCT with different clinical courses. Case 1 was a cystic, slow growing tumor with mild vascularity. The tumor was removed one week after delivery at 35 weeks, and there was no recurrence at 1.5-year follow-up. Case 2 was a solid, rapid growing tumor with rich vascularity. Cesarean section was performed due to severe fetal hydrops and mirror syndrome in the mother at 27 weeks. The tumor had ruptured and was removed soon after delivery to control bleeding, but the baby died the next day. Our cases suggest that solid component and rich vascularity might correlate with poor prognosis.
© 2012 The Authors. Congenital Anomalies © 2012 Japanese Teratology Society.

Entities:  

Mesh:

Year:  2013        PMID: 23751044     DOI: 10.1111/j.1741-4520.2012.00369.x

Source DB:  PubMed          Journal:  Congenit Anom (Kyoto)        ISSN: 0914-3505            Impact factor:   1.409


  3 in total

1.  Multi-stage resection and repair for the treatment of adult giant sacrococcygeal teratoma: A case report and literature review.

Authors:  Qin-Song Sheng; Xiang-Ming Xu; Xiao-Bin Cheng; Wei-Bing Wang; Wen-Bin Chen; Jian-Jiang Lin; Jia-He Xu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

2.  Unresectable recurrence malignant sacrococcygeal teratoma in children treated with chemoradiotherapy: Case report and literature review.

Authors:  Yecai Huang; Mei Feng; Jun Yin; Bingyu Fu; Jinyi Lang
Journal:  Rep Pract Oncol Radiother       Date:  2019-06-22

3.  A Clinical Analysis of the Diagnosis and Treatment of Fetal Sacrococcygeal Teratomas.

Authors:  Xiu-Qiong Zheng; Rong-Li Xu; Jian-Ying Yan; Xue-Chun Wang; Xian Chen; Ke-Hua Huang
Journal:  Cancer Manag Res       Date:  2020-12-23       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.